US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

Invitation to presentation of Q-linea’s Interim report Q3-2020 on November 5, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – September 2020 on Thursday, November 5, 2020 at 07:30 a.m. CET.Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on November 5, 2020, at 1:00 – 2:00 p.m CET. Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Q3 interim report followed by a Q&A-session.   To participate, please call any of the following phone numbers from: Sweden: + 46 8 566 427 04 UK: + 44 333 300 9268 US: + 1 833 249

Webinar Tuesday November 10th: Equal and better care for everyone

Q-linea AB (publ) (OMX: QLINEA), invites you to a webinar with presentations followed by a Q&A session by CEO Jonas Jarvius, Research Director Mats Gullberg and Marketing & Sales Director Charlotta Göransson.Date: November 10thTime: 17.00 CET, 11 AM EDT, 8 AM PDTDuration: 1 hour On the agenda: · How ASTar meets the challenges in the lab and clinic, and help improve patient outcomes · Sneak peek on an upcoming exciting product · Q&A session - get answers to your questions Learn more and register here:https://www.qlinea.com/webinar-registration A link to the webinar

Q-linea enters into an agreement with Hvidovre Hospital as a participant in the clinical study

Q-linea AB (publ) (OMX:QLINEA), today announced that Hvidovre Hospital in Denmark will participate in the company's European pivotal clinical study, which will start in the autumn of 2020. Through the choice of Hvidovre Hospital, Q-linea has now chosen the sites required to be able to start the prospective performance study with 80 to 100 patients during the autumn of 2020. The study will take place internally at Q-linea, at Hvidovre Hospital and at Uppsala University Hospital. “The interest in testing ASTar® has been great from several hospitals and I am very happy that Hvidovre

Q-linea installs the first ASTar system at Uppsala University Hospital

Q-linea AB (publ) (OMX: QLINEA), today announced that an ASTar® instrument is now being used for beta testing at Uppsala University Hospital and that the hospital will participate in the company's European pivotal clinical study.Following this spring's collaboration with the laboratory for clinical microbiology at Uppsala University Hospital, Q-linea has now installed an ASTar instrument for evaluation at the hospital for the upcoming pivotal clinical study. “It is an important step for us that ASTar now will be evaluated in a real laboratory environment by a potential customer. Uppsala

INTERIM REPORT 1 JANUARY – 30 JUNE 2020

Strong study results and virtual presentation of ASTar Second quarter, 1 April –30 June 2020 · Net sales amounted to SEK 0.1 million (0.5). · The operating result totalled SEK -58.6 million (-44.5). · The result for the period amounted to SEK -57.4 million (-44.0). · Earnings per share before and after dilution amounted to SEK -2.37 (-1.92). · Cash flow from operating activities totalled SEK -54.8 million (-40.9). Period, 1 January–30 June 2020 · Net sales amounted to SEK 0.2 million (1.0). · The operating result totalled SEK -114.5 million (-81.2). · The

Invitation to presentation of Q-linea’s Interim report Q2-2020 on July 16, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – June 2020 on Thursday, July 16, 2020 at 07:30 a.m. CET. Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on July 16, 2020, at 13:00 – 14:00 p.m CET. Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Q2 interim report followed by a Q&A-session.     To participate, please call any of the following phone numbers from: Sweden: + 46 8 519 993 83 UK: + 44 333 300 9269 US: + 1 844 625

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of June due to the direct issue of shares to certain Swedish and international institutional investors and sector specialist investors. The press release regarding the issue of shares was published on 2 June 2020. A total of 4,000,000 ordinary shares and votes have been added. At 30 June 2020, which is the last trading day in June, the number of shares and votes in the Company amounts to 27,337,947. All shares are ordinary shares.   For

BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

Q-linea AB (publ) (OMX:QLINEA), Today on 26 May 2020, Q-linea AB (publ) (the “Company”) held its annual general meeting for the financial year 2019 in Uppsala, whereby the resolutions below were adopted. For more detailed information on the content of the resolutions, please see the complete notice of the annual general meeting. The notice of the annual general meeting and the complete proposals are available on the Company’s website, www.qlinea.com. Minutes from the annual general meeting will be provided on the said website within two weeks from the day of the meeting. Adoption of

Webinar Friday June 5th: How can we improve infection diagnostics with ASTar

Q-linea AB (publ) (OMX: QLINEA), invites you to a webinar on June 5[th ]at 2pm and 7pm CEST with presentations by CEO Jonas Jarvius, Research Director Mats Gullberg and Marketing & Sales Director Charlotta Göransson.On the agenda: · Presentation of Q-linea and our leading product ASTar[®] · Presentation of the technology behind ASTar – ASTar is designed to deliver the most accurate and complete result for rapid phenotypic AST. · Demonstration of the features of ASTar and how to perform a run. Learn more and register here:https://www.qlinea.com/webinar-registration/ A link

Q-linea announces positive results from prospective study with ASTar

Q-linea AB (publ) (OMX: QLINEA), today announced positive results from a prospective patient study conducted together with Uppsala University Hospital. In the study, the ASTar system analyzed samples from 17 patients and the antibiotic panel consisted of 29 anti-biotics. The results were very good and was well above regulatory requirements for EU and US. The study was conducted in collaboration with the laboratory for clinical microbiology at Uppsala University Hospital. For three weeks, samples from 17 patients were collected and thereafter transported to Q-linea for analysis on ASTar.

INTERIM REPORT 1 JANUARY – 31 MARCH 2020

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTarFirst quarter, 1 January –31 March 2020 · Net sales amounted to SEK 0.2 million (0.4). · The operating result totalled SEK -55.9 million (-36.7). · The result for the period amounted to SEK -56.0 million (-36.3). · Earnings per share before and after dilution amounted to SEK -2.44 (-1.59). · Cash flow from operating activities totalled SEK -59.1 million (-41.0). · At 31 March 2020, cash and cash equivalents amounted to SEK 28.3 million (26.0). Short-term investments in fixed-

Invitation to presentation of Q-linea’s Interim report Q1-2020 on May 7, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – March 2020 on Thursday, May 7, 2020 at 07:30 a.m. CET. Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on May 7, 2020, at 13:00 – 14:00 p.m CET.Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Q1 interim report followed by a Q&A-session.To participate, please call any of the following phone numbers from: Sweden: + 46 8 505 583 52 UK: + 44 333 300 9261 US: + 1 833 249 8403 Webcast:

NOTICE OF ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Tuesday 26 May 2020, at 4 pm in Konferens Hubben (conference room 3+4) with address Dag Hammarskjölds väg 38, 752 37 Uppsala. Right to attend the annual general meeting Shareholders who wish to participate at the annual general meeting must on Tuesday 19 May 2020 be registered in the share register kept by Euroclear Sweden AB, and notify his or her intention to attend the annual general meeting by email to q-linea@lindahl.se, by telephone to +46 (0)18 16 18

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 26 May 2020, with regard to the number and election of members of the board of directors. The nomination committee proposes seven members of the board of directors and no deputy directors. The nomination committee proposes that Erika Kjellberg Eriksson, Mats Nilsson, Marianne Hansson, Marcus Storch, Per-Olof Wallström and Hans Johansson be re-elected as board members and that Mario Gualano be elected as new board member, each for a

Q-linea publish the Annual report for 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2019 fiscal year has been published. The Annual Report is attached and can also be downloaded from the company’s website, www.qlinea.com     For more information, please contact: Anders Lundin, CFO, Q-linea ABanders.lundin@qlinea.com+46 (0)70-600 15 20 This information is information that Q-linea AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08:30 CET on April 17, 2020. About Q-linea Q-linea is an

Q-linea has solved the component problem

Q-linea AB (publ) (OMX: QLINEA), today announced that the problem discovered in October last year has now been solved. With respect to the component that previously caused a delay in the clinical trials eight ASTar systems have now worked flawlessly since November.In October 2019, Q-linea identified problems with an important component from a third-party manufacturer. Together with the component manufacturer, Q-linea quickly identified and corrected the minor modifications and improvements that needed to be made. The solution has now been tested on eight ASTar systems that have worked

YEAR-END REPORT 1 JANUARY – 31 DECEMBER 2019

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar intensifies ahead of ASTar launchFourth quarter, 1 October–31 December 2019 · Net sales amounted to SEK 0.0 million (0.3). · The operating result totalled SEK -62.1 million (-39.0). · The result for the period amounted to SEK -62.0 million (-39.4). · Earnings per share before and after dilution amounted to SEK -2.71 (-2.33). · Cash flow from operating activities totalled SEK -52.1 million (-37.4). Period, 1 January–31 December 2019 · Net sales amounted to SEK 1.0 million (1.

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar

Q-linea AB (publ) (OMX: QLINEA), today announced that the company has entered into a worldwide exclusive partnership with Thermo Fisher Scientific for the commercialization of ASTar.“We are very happy and proud to be able to present an important commercial milestone for both companies. The interest in commercializing ASTar® has been very strong from a number of global companies. We are thrilled to be working with Thermo Fisher and especially appreciate their global reach. We share a common market view and agree on how infection diagnosis can be improved.” said Jonas Jarvius, CEO of Q-linea.

Invitation to presentation of Q-linea’s Year End Report Q4-2019 on February 13, 2020

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Year End Report for the period January – December 2019 on Thursday, February 13, 2020 at 07:30 a.m. CET. Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on February 13, 2020, at 13:30 – 14:30 p.m CET. Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Year End Report followed by a Q&A-session.       To participate, please call any of the following phone numbers from: Sweden: + 46 8 505 583 51 UK: + 44 333 300 9273 US: +

Change in the number of shares and votes in Q-linea AB

Q-linea AB (publ) (”Q-linea” or ”the Company”), today announced that the number of shares and votes in Q-linea has increased during the month of January due to subscription of new shares on exercise of warrants to ensure delivery of shares within the framework of the employee stock option programme that was resolved by the annual general meeting 2011. A total of 102,560 shares and votes have been added. At 31 January 2020, which is the last trading day in January, the number of shares and votes in the Company amounts to 23,337,947. All shares are ordinary shares.  For further

INTERIM REPORT 1 JANUARY – 30 SEPTEMBER 2019

A quarter of intense preparation Third quarter, 1 July - 30 September 2019 · Net sales amounted to SEK 0.0 million (0.3). · The operating result totalled SEK -35.8 million (-28.8). · The result for the period amounted to SEK -35.1 million (-29.3). · Earnings per share before and after dilution amounted to SEK -1.53 (-1.98). · Cash flow from operating activities totalled SEK -35.8 million (-31.2). Period, 1 January - 30 September 2019 · Net sales amounted to SEK 1.0 million (0.8). · The operating result totalled SEK -117.1 million (-88.4). · The result for

Invitation to presentation of Q-linea’s Interim Report Q3-2019 on November 7, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – September 2019 on Thursday, November 7, 2019 at 07:30 a.m. CET. Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on November 7, at 13:00 – 14:00 p.m CET. Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Interim Report Report for the period January – September 2019 followed by a Q&A-session. To participate, please call any of the following phone numbers from: Sweden: + 46 8 566 427 05

Q-linea receives positive response from the FDA for the design of the company's planned clinical study in the USA

Q-linea AB (publ) (OMX: QLINEA, announced today that the company has received the official response including a number of clarifications and very positive feedback from the US Food and Drug Administration, FDA, regarding the company's planned pivotal clinical trial with ASTar® in the United States.“We are very pleased with the official feedback from the FDA which will have a very positive impact on the conduct of our clinical study in the US. We have received the clear guidance we wanted and we believe that the study can be carried out in a more straightforward way than previously estimated,

There are no items matching the current filter
There are no more items matching the current filter
Back to top